A survey of susoctocog alfa for acquired hemophilia A
Part of Blood & lymphatic clinical trials.
This trial is studying a medication called susoctocog alfa for people with acquired hemophilia A, a bleeding disorder. It aims to understand how well the treatment works and how it is being used.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with acquired hemophilia A
- You must have been treated with susoctocog alfa
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called Bometase Alfa to help control bleeding in people with acquired hemophilia A, a rare condition where the immune system attacks a clotting protein. If you have active bleeding from this condition, this treatment might help stop it.
This study is tracking how well Alhemo works in people with hemophilia A or B who have developed inhibitors (antibodies that block treatment). It is for patients of any age who have already started taking Alhemo as part of their regular care.
This trial will track how well Alhemo works and how safe it is for people with hemophilia A or B in everyday use. If you are 12 or older and your doctor has already decided to start you on Alhemo, this study will collect information to help doctors better understand the medicine's real-world benefits and risks.
This study is looking at the safety and effectiveness of a factor VIII medicine called octocog alfa (used to treat bleeding) in men with severe hemophilia A in India. It will track how well the medicine works and any side effects during routine care.
This trial studies whether a CD38-targeting antibody together with corticosteroids can improve outcomes in acquired hemophilia A. It is an “exploratory” Phase 4 study, meaning the goal is to learn more about safety and effectiveness in real-world patients.
This study looks at how well a medicine called damoctocog alfa pegol (Jivi) works to prevent bleeding in children with hemophilia A. It will follow children who are already using this medicine or starting it, to see how effective it is in real life.
Hear when a new Acquired Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.